Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma

Chinese Clinical Oncology
Vishal Jindal

Abstract

Uveal melanoma (UM) is one of the rare malignancies, which can be lethal despite local treatment. Treatment options available now can control UM in early stages, but once it metastasized to distant organs especially liver, prognosis is poor. Immune checkpoint inhibitors (ICIs) are the new revolutionary treatment in management of metastatic cutaneous melanoma. UM and cutaneous melanoma are similar as both of them derived from melanocytes but in terms of mutational load and expression of antigens they are distinct. In most of clinical trials of melanoma, UM patients were excluded and up till now there are only few studies regarding role of ICIs in metastatic UM. Most of these studies showed poor outcome and low survival benefit. Currently, research is going on combinational therapies and novel immunotherapy options. Here in this article we will discuss results of studies regarding ICIs in UM, ongoing trials and new immunotherapeutic options of UM.

Citations

Nov 17, 2019·International Journal of Molecular Sciences·Cristina Maria FaillaStefania D'Atri
Mar 25, 2020·International Ophthalmology Clinics·Jonathan E LuSandy Zhang-Nunes
Jul 6, 2019·Current Medicinal Chemistry·Snježana KaštelanKoraljka Hat
Mar 26, 2019·International Ophthalmology Clinics·Annemijn P A WierengaMartine J Jager
Jun 20, 2020·Therapeutic Advances in Medical Oncology·Meng-Yu WuChia-Jung Li
Aug 27, 2019·Current Opinion in Ophthalmology·Vivian Paraskevi DouglasDean M Cestari
Oct 30, 2020·Clinical Ophthalmology·Anastasia Gkiala, Sotiria Palioura
May 28, 2021·Melanoma Research·Seher Yildiz TacarDeniz Tural

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Current Treatment Options in Oncology
Urvi A ShahLakshmi Rajdev
Current Opinion in Oncology
Simone M GoldingerPaul D Nathan
© 2022 Meta ULC. All rights reserved